HeartBeam Advances Heart Attack Detection Program, Extends Cash Runway Into 2027

HeartBeam Inc. (NASDAQ: BEAT) has reported its second-quarter 2026 financial and operational results, highlighting significant strides in its heart attack detection program, the development of its 12-lead ECG extended wear patch, and the initial commercial launch of its technology. The company completed enrollment of 134 patients in its ALIGN-ACS pilot study ahead of schedule, with full results expected to be presented at TCT 2026, and has surpassed 50% enrollment in its 500-patient HEADSTART-ACS pilot study. These studies are critical for validating the company's innovative approach to detecting heart attacks outside of traditional medical settings.

In addition to clinical progress, HeartBeam has completed a working prototype of its 12-lead ECG extended wear patch, a key component of its product portfolio. The company has also signed multiple commercial agreements across four targeted U.S. geographies, shipped its first orders, and onboarded initial patients. This marks a pivotal step in transitioning from development to commercialization, positioning HeartBeam to address the critical need for accessible cardiac monitoring.

Financially, HeartBeam reported a second-quarter net loss of $5 million, or $0.10 per basic and diluted share, consistent with the year-ago period. Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026. The company expects full-year 2026 net operating cash outflow to be below $14 million, which, combined with its current cash position, extends its cash runway into 2027. This financial stability provides the company with the resources needed to advance its clinical programs and commercial rollout.

The significance of these developments lies in HeartBeam's mission to transform cardiac care through its patented 3D ECG technology, which has received FDA clearance for arrhythmia assessment and 12-lead ECG synthesis. By enabling patients to capture ECG signals in 3D from non-coplanar directions and synthesize them into a 12-lead ECG, the platform allows for actionable heart intelligence that can be used anywhere, potentially reducing delays in diagnosing heart attacks. The company's progress in clinical studies and early commercialization underscores its potential to improve patient outcomes and reduce healthcare costs associated with cardiac events.

For more information on HeartBeam's recent announcements and its technology, visit the company's newsroom at https://ibn.fm/BEAT and the cleared indications for use at https://www.heartbeam.com/indications.